The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Postmarketing Safety Study of Hemoporfin in Patients With Port Wine Stain
Official Title: Postmarketing Safety Study of Hemoporfin in Patients With Port Wine Stain
Study ID: NCT03181984
Brief Summary: This study is to provide safety information of hemoporfin during the post-marketing period as required by China Food and Drug Administration (CFDA) regulations in order to identify any potential drug related treatment factors in the Chinese population, such as unknown/unexpected adverse reactions, the incidence of adverse reactions under the routine drug uses.
Detailed Description:
Minimum Age: 14 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
The 2nd Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
Affiliated Hospital of Hebei Medical College of traditional Chinese Medicine, Shijiazhuang, Herbei, China
Wuxi People's Hospital, Wuxi, Jiangsu, China
West China Hospital, Sichuan University, Chengdu, Sichuan, China
Peking University First Hospital, Beijing, , China
PLA Army General Hospital, Beijing, , China
Shanghai Dermatology Hospital, Shanghai, , China
Name: Xuejun Zhu
Affiliation: Peking University First Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Jining Tao
Affiliation: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Role: STUDY_DIRECTOR